AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28487139 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramped position
Number of subjects: 260
Study 28487139 — intervention group
Group type: COMPARATOR
Intervention: Sniffing position
Number of subjects: 260
Study 26076171 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol (100 mg immediate release tablet)
Number of subjects: 12
Study 26076171 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (40 mg immediate release tablet)
Number of subjects: 12
Study 26076171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23507370 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS treatment
Number of subjects: 0
Study 23507370 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 21444883 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote telemedical management (RTM)
Number of subjects: 710
Study 21444883 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 710
Study 19429451 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume upper-body resistance exercise (HT)
Number of subjects: 6
Study 19429451 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) trial
Number of subjects: 6
Study 16420392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin 10 ml
Number of subjects: 279
Study 16420392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin 30 ml
Number of subjects: 279
Study 16420392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin 60 ml
Number of subjects: 279
Study 16420392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 16162200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-based immunosuppression
Number of subjects: 40
Study 16162200 — intervention group
Group type: COMPARATOR
Intervention: CNI-based immunosuppression (cyclosporin or tacrolimus)
Number of subjects: 40
Study 12777437 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up survey in 1997
Number of subjects: 3499
Study 12777437 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors
Number of subjects: 3499
Study 9674619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed intervention containing guidelines for the use of sedative hypnotics, a prescriber profile detailing sedative hypnotic prescribing, and a patient profile
Number of subjects: 189
Study 9674619 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 189
Study 9674619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed intervention
Number of subjects: 189
Study 7639342 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg d-alpha-tocopherol per day for 3 weeks
Number of subjects: 15
Study 7639342 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg d-alpha-tocopherol per day for 3 weeks
Number of subjects: 15
Study 7639342 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg d-alpha-tocopherol per day for 3 weeks
Number of subjects: 15
Study 2515041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg
Number of subjects: 65
Study 2515041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 500 mg
Number of subjects: 65
Study 340329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg daily at bedtime
Number of subjects: 60
Study 340329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30093372 — intervention group
Group type: EXPERIMENTAL
Intervention: iPST (problem-solving therapy)
Number of subjects: 1040
Study 30093372 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Evolution (cognitive training app)
Number of subjects: 1040
Study 30093372 — intervention group
Group type: COMPARATOR
Intervention: Health tips (information control)
Number of subjects: 1040
Study 29691559 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAP laser disinfection
Number of subjects: 40
Study 29691559 — intervention group
Group type: COMPARATOR
Intervention: Hoshino's triple antibiotic paste (Control)
Number of subjects: 40
Study 26261326 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocative messages delivered on stickers inside matatus
Number of subjects: 12000
Study 26261326 — intervention group
Group type: COMPARATOR
Intervention: Complementary radio campaign
Number of subjects: 12000
Study 23770747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 5851
Study 23770747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 5851
Study 21111873 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of informational posters in endoscopy rooms within view of operators and nurses.
Number of subjects: 778
Study 21111873 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical cohort).
Number of subjects: 778
Study 18807742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough of > or = 14 days in survey I
Number of subjects: 82000
Study 18807742 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic subjects with cough in surveys II and III
Number of subjects: 82000
Study 18807742 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms without cough but with chest pain > or = 1 month in survey I
Number of subjects: 82000
Study 18807742 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms without cough but with chest pain > or = 1 month in survey II
Number of subjects: 82000
Study 18807742 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms without cough but with chest pain > or = 1 month in survey III
Number of subjects: 82000
Study 18807742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever > or = 1 month
Number of subjects: 82000
Study 16162703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 mug)
Number of subjects: 261
Study 16162703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 14587651 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg/day)
Number of subjects: 60
Study 14587651 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day)
Number of subjects: 60
Study 14587651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR (20 mg/day)
Number of subjects: 60
Study 10566466 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to pain management information on the ambulatory surgery website
Number of subjects: 195
Study 8722940 — intervention group
Group type: EXPERIMENTAL
Intervention: HRC regimen (isoniazid 300 mg, rifampin 600 mg, ciprofloxacin 750 mg)
Number of subjects: 200
Study 8722940 — intervention group
Group type: COMPARATOR
Intervention: HRZE regimen (isoniazid 300 mg, rifampin 600 mg, pyrazinamide 25 mg/kg, ethambutol 15 mg/kg)
Number of subjects: 200
Study 1910795 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 ml of apple juice, 150 mg of oral ranitidine (two doses), 10 mg of metoclopramide
Number of subjects: 83
Study 1910795 — intervention group
Group type: COMPARATOR
Intervention: Fasting with acid aspiration prophylaxis identical to Group 1
Number of subjects: 83
Study 1910795 — intervention group
Group type: COMPARATOR
Intervention: No oral fluids or acid aspiration prophylaxis
Number of subjects: 83
Study 6761928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 2 mg pessaries administered four hourly
Number of subjects: 0
Study 30489177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib low-dose (1 or 3 mg) with low-dose MTX
Number of subjects: 254
Study 30489177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib low-dose (1 or 3 mg) with high-dose MTX
Number of subjects: 254
Study 30489177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID with low-dose MTX
Number of subjects: 254
Study 30489177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID with high-dose MTX
Number of subjects: 254
Study 30489177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID with low-dose MTX
Number of subjects: 254
Study 30489177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID with high-dose MTX
Number of subjects: 254
Study 30489177 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low-dose MTX
Number of subjects: 254
Study 30489177 — intervention group
Group type: COMPARATOR
Intervention: Placebo with high-dose MTX
Number of subjects: 254
Study 27913227 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate assisted partner services
Number of subjects: 1305
Study 27913227 — intervention group
Group type: COMPARATOR
Intervention: Delayed assisted partner services
Number of subjects: 1305
Study 25813240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (L.GG)
Number of subjects: 40
Study 25813240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23939544 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 17
Study 22979911 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (15% cetrimide, 1.5% Chlorhexidine-gluconate, ethanol)
Number of subjects: 50
Study 22979911 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine (10% povidone-iodine)
Number of subjects: 50
Study 19407731 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (2-20 mg/day)
Number of subjects: 1147
Study 19407731 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 1147
Study 19407731 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 1147
Study 17387446 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 296
Study 17387446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 16279260 — intervention group
Group type: EXPERIMENTAL
Intervention: Eformoterol
Number of subjects: 27
Study 16279260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 10769852 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing
Number of subjects: 155
Study 10769852 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional cleaning with a rubber cup
Number of subjects: 155
Study 10769852 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling
Number of subjects: 155
Study 9060541 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant goserelin
Number of subjects: 945
Study 9060541 — intervention group
Group type: COMPARATOR
Intervention: Observation arm
Number of subjects: 945
Study 9060541 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant goserelin (in patients with Gleason score 8 to 10)
Number of subjects: 945
Study 9060541 — intervention group
Group type: COMPARATOR
Intervention: Observation arm (in patients with Gleason score 8 to 10)
Number of subjects: 945
Study 8394849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium (10,000 IU daily for weeks 1 and 2, 5,000 IU daily for weeks 3 and 4)
Number of subjects: 23
Study 8394849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium
Number of subjects: 23
Study 8394849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3097709 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.03 mg/kg body wt.)
Number of subjects: 6
Study 3097709 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 6
Study 28675892 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 0
Study 28675892 — intervention group
Group type: EXPERIMENTAL
Intervention: Eurythmy therapy
Number of subjects: 0
Study 28675892 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic exercises
Number of subjects: 0
Study 27391158 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT plus consolidation chemotherapy
Number of subjects: 146
Study 27391158 — intervention group
Group type: COMPARATOR
Intervention: CRT alone
Number of subjects: 146
Study 24535848 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation using a tablet PC during chemotherapy infusion (n=19)
Number of subjects: 36
Study 24535848 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=17)
Number of subjects: 36
Study 22728750 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 264
Study 22728750 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 264
Study 22728750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both albendazole and praziquantel)
Number of subjects: 264
Study 22728750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookworm and Trichuris infections
Number of subjects: 264
Study 20083245 — intervention group
Group type: EXPERIMENTAL
Intervention: TiF4
Number of subjects: 10
Study 20083245 — intervention group
Group type: EXPERIMENTAL
Intervention: ZrF4
Number of subjects: 10
Study 20083245 — intervention group
Group type: EXPERIMENTAL
Intervention: HfF4
Number of subjects: 10
Study 20083245 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF
Number of subjects: 10
Study 20083245 — intervention group
Group type: COMPARATOR
Intervention: Control (unfluoridated samples)
Number of subjects: 10
Study 18932271 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (neuroprotective therapy)
Number of subjects: 1176
Study 18932271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1176
Study 15800147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 56
Study 15800147 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 56
Study 15800147 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific supportive clinical management
Number of subjects: 56
Study 12870166 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Intralipid infusion (0.4 mL(‐1) x kg(‐1) x h(‐1))
Number of subjects: 15
Study 10420420 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose emotional expression writing group
Number of subjects: 44
Study 10420420 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose emotional expression writing group
Number of subjects: 44
Study 10420420 — intervention group
Group type: COMPARATOR
Intervention: Attentional control group
Number of subjects: 44
Study 7594351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 93
Study 7594351 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 93
Study 1966304 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarin
Number of subjects: 11
Study 7194061 — intervention group
Group type: EXPERIMENTAL
Intervention: etofylline clofibrate (3 x 250 mg)
Number of subjects: 20
Study 7194061 — intervention group
Group type: COMPARATOR
Intervention: standard preparation (clofibrate 3 x 500 mg and beta-pyridylcarbinol hydrogentartrate 3 x 25 mg)
Number of subjects: 20
Study 30627959 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised clinical trials in obstetrics
Number of subjects: 9967
Study 29768709 — intervention group
Group type: EXPERIMENTAL
Intervention: IMQ (5 mg) applied once daily for 72 hours under occlusion to tape stripped skin (n = 8)
Number of subjects: 16
Study 29768709 — intervention group
Group type: EXPERIMENTAL
Intervention: IMQ (5 mg) applied once daily for 72 hours under occlusion to intact skin (n = 8)
Number of subjects: 16
Study 29768709 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 16
Study 26500351 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (50, 100, 300, or 600 mg) plus chloroquine
Number of subjects: 0
Study 26500351 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus primaquine
Number of subjects: 0
Study 26500351 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 0
Study 24268371 — intervention group
Group type: COMPARATOR
Intervention: Standard 14-day quadruple treatment (Rabeprazole 20mg-bid, bismuth subcitrate 120 mg-qid, Tetracycline 500 mg-qid, Metronidazole 500 mg-tid for 2 weeks)
Number of subjects: 160
Study 24268371 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (20 mg rabeprazole and 1g amoxicillin twice daily for the first 5 days, followed by standard quadruple treatment for the remaining 5 days)
Number of subjects: 160
Study 24268371 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-day sequential therapy (20 mg rabeprazole and 1g amoxicillin twice daily for the first 5 days, followed by standard quadruple treatment for the remaining 7 days)
Number of subjects: 160
Study 24268371 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day sequential therapy (20 mg rabeprazole and 1g amoxicillin twice daily for the first 5 days, followed by standard quadruple treatment for the remaining 9 days)
Number of subjects: 160
Study 22507748 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with iron (60-120mg) plus folic acid (0.4mg)
Number of subjects: 100
Study 22507748 — intervention group
Group type: COMPARATOR
Intervention: Weekly supplementation with 120mg iron plus various amounts of folic acid
Number of subjects: 100
Study 20199521 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide (25-60 mg/kg/day)
Number of subjects: 124
Study 17664149 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g intravenous infusion)
Number of subjects: 18
Study 17664149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16225161 — intervention group
Group type: EXPERIMENTAL
Intervention: MR carbonyl iron (45 mg)
Number of subjects: 60
Study 16225161 — intervention group
Group type: COMPARATOR
Intervention: Ferrous fumarate (300 mg)
Number of subjects: 60
Study 11818358 — intervention group
Group type: EXPERIMENTAL
Intervention: Family physicians (FPs) recruitment
Number of subjects: 889
Study 11818358 — intervention group
Group type: EXPERIMENTAL
Intervention: Seniors recruitment
Number of subjects: 889
Study 11818358 — intervention group
Group type: EXPERIMENTAL
Intervention: Seniors refusal rates
Number of subjects: 889
Study 9806669 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) at 12.5 ng x kg(‐1) x min(‐1)
Number of subjects: 40
Study 9806669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7631683 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron prophylaxis
Number of subjects: 2693
Study 7631683 — intervention group
Group type: COMPARATOR
Intervention: Iron only if needed
Number of subjects: 2693
Study 2575987 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol
Number of subjects: 211
Study 2575987 — intervention group
Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 211
Study 333957 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (relaxation response technique)
Number of subjects: 126
Study 333957 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (sit quietly)
Number of subjects: 126
Study 333957 — intervention group
Group type: COMPARATOR
Intervention: Group C (no instructions)
Number of subjects: 126
Study 7323701 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-side jejunoileostomy
Number of subjects: 26
Study 7323701 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end jejunoileostomy
Number of subjects: 26
Study 7323701 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 26
Study 7323701 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study 31592939 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (1.6 × 10 colony‐forming units of Lactobacillus rhamnosus capsules)
Number of subjects: 44
Study 31592939 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (maltodextrin capsules)
Number of subjects: 44
Study 29425140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature slideshow
Number of subjects: 58
Study 29425140 — intervention group
Group type: COMPARATOR
Intervention: Urban slideshow
Number of subjects: 58
Study 29425140 — intervention group
Group type: COMPARATOR
Intervention: No distractions (control group)
Number of subjects: 58
Study 26781763 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU) and Evening Primrose Oil (1000 mg)
Number of subjects: 60
Study 26781763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25401501 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum selenium deficiency (<85 μg/L) pre-ART
Number of subjects: 0
Study 25401501 — intervention group
Group type: COMPARATOR
Intervention: Third quartile serum selenium (74.86-95.10 μg/L)
Number of subjects: 0
Study 22863643 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release therapy + Kinesiotherapy
Number of subjects: 65
Study 19781696 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 19781696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17376037 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal EGD
Number of subjects: 124
Study 17376037 — intervention group
Group type: COMPARATOR
Intervention: Peroral EGD
Number of subjects: 124
Study 16320441 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step practices (number of meetings attended, prescribed activities engaged)
Number of subjects: 302
Study 16320441 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific 12-step activities (having a sponsor, doing service)
Number of subjects: 302
Study 16320441 — intervention group
Group type: EXPERIMENTAL
Intervention: Service work in AA and/or Narcotics Anonymous
Number of subjects: 302
Study 16320441 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportion of abstinent individuals in the social network
Number of subjects: 302
Study 16320441 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step measures thresholds (e.g., >20 meetings for alcoholics, 2 or more nondrinkers in the social network)
Number of subjects: 302
Study 16320441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing 12-step involvement (sponsor and meetings)
Number of subjects: 302
Study 16320441 — intervention group
Group type: EXPERIMENTAL
Intervention: Doing service
Number of subjects: 302
Study 12221027 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint Program (intervention group receiving persuasive communications)
Number of subjects: 452
Study 12221027 — intervention group
Group type: COMPARATOR
Intervention: General information about driving safety (comparison group)
Number of subjects: 452
Study 10212042 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 44